 |
This article needs additional citations for verification. Please help improve this articlebyadding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "Sakigake" drug designation – news · newspapers · books · scholar · JSTOR (July 2021) (Learn how and when to remove this message) |
Sakigake (さきがけ, lit. "pathfinder", "harbinger") is a drug designation by the Pharmaceuticals and Medical Devices Agency, the pharmaceuticals regulator of Japan. It was designed to provide easier access to novel advanced treatments.[1] It is analogous to the Regenerative Medicine Advanced Therapy designation in the United States and the Advanced Therapy Medicinal Product designation in the European Union.
The Sakigake designation was first announced as a pilot by the Ministry of Health, Labour and Welfare on 17 June 2014. The designation system is part of a wider strategy, also named Sakigake, to promote R&D and improve access to new pharmaceuticals.[2] The Pharmaceutical & Medical Device Act Amendments of 2019, which entered into force on 1 September 2020, made the Sakigake designation system a permanent fixture.[3] While application for the Sakigake designation was only open for a short period every year, the permanent Sakigake regime is open year-round.
The Sakigake designation opens up the possibility for sponsors to seek pre-application consultations, which provide clients with a fixed-price multi-track review of their application.[4]
As of 31 December 2020[update], 24 drugs received Sakigake designation, but only 8 of these (33.33%) were approved.[3]
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
